H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $51 from $44 at TD Cowen
- Exelixis price target raised to $43 from $41 at Stifel
- Exelixis price target raised to $41 from $40 at Barclays
- Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
- Exelixis Reports Strong Q3 2025 Financial Results